Holen Sie sich die Stockscreener-App
0.02
900.00%
0.018
Nkgen Biotech Inc Aktie (NKGN) Neueste Nachrichten
NKGen Biotech provides clarification on quotation display, trading status - TipRanks
NKGen Biotech Provides Clarification on Quotation Display and Trading Status on the OTC Expert Market - The Manila Times
Form 10-K Filed Oct 8, 2025 — NKGen Biotech clarifies OTC Expert Market quotes; Common Stock remains tradable - Stock Titan
NKGen Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - MarketScreener
NKGen Biotech to Present on the Use of Troculeucel for - GlobeNewswire
NKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the XXVII World Congress of Neurology - The Manila Times
NKGen to Present Troculeucel for Alzheimer's at WCN Oct 15 | NKGN Stock News - Stock Titan
NKGen Biotech (NYSE:NKGN) versus AlloVir (NASDAQ:ALVR) Critical Analysis - Defense World
NKGen Biotech Announces Consulting Agreement with Dr. Kim - MSN
NKGen Biotech Secures $2.5M in Stock Purchase Agreement - TipRanks
NKGen Biotech enters $2.5 million stock and warrant agreement with Asia Advisors - Investing.com Nigeria
NKGen Biotech enters $2.5 million stock and warrant agreement with Asia Advisors By Investing.com - Investing.com South Africa
NKGen Biotech CEO to present NK cell therapy data at China forum - Investing.com Australia
Breakthrough NK Cell Therapy for Neurodegenerative Diseases: NKGen Biotech Presents Latest Clinical Data - Stock Titan
LadRx (OTCMKTS:CYTR) & NKGen Biotech (NYSE:NKGN) Head-To-Head Analysis - Defense World
NKGen Biotech announces completion of NKMax acquisition - MSN
NKGen Biotech Acquires Majority Stake in NKMax - TipRanks
NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. Acquisition; Gains Full Control of Global Manufacturing and Intellectual Property Assets - The Manila Times
NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. - GlobeNewswire
$16.9M Strategic Acquisition: NKGen Biotech Gains Full Control of NK Cell Therapy Manufacturing & IP Portfolio - Stock Titan
Cell Dissociation Market Size Projected to Attain USD 1,451.89 Million by 2034 - GlobeNewswire
Alzheimer's Disease Pipeline 2025: Detailed Clinical Trials And FDA-Approved Therapies Review By Delveinsight Neurodon, Sangamo Therapeutics, Nkgen Biotech, Asceneuron, Truebinding, Alector - MenaFN
NKGen Biotech announces new funding to regain compliance with reporting obligations and listing standards - MSN
NKGen Biotech, Inc. (NYSE:NKGN) Short Interest Update - Defense World
NKGen Biotech To Present on Allogeneic Enhanced NK Cells - GlobeNewswire
Breakthrough: NKGen's NK Cell Cancer Therapy Eliminates Need for Harsh Pre-Treatment in Solid Tumors - Stock Titan
NKGen Biotech To Present on Allogeneic Enhanced NK Cells without Lymphodepletion in Solid Tumors at the 13th Annual Immuno-Oncology Summit - Yahoo Finance
Critical Contrast: NKGen Biotech (NYSE:NKGN) & Cortexyme (NASDAQ:CRTX) - Defense World
NKGen Biotech Presents Troculeucel Mechanism of Action with - GlobeNewswire
Revolutionary NK Cell Therapy Transforms Moderate Alzheimer's to Mild Stage in Clinical Trial - Stock Titan
NKGen Biotech to Present at the Alzheimer’s Association International Conference 2025 - GlobeNewswire
Revolutionary NK Cell Therapy Shows Promise in Alzheimer's Disease: Phase 1 Data Reveal Key Insights - Stock Titan
NKGen Biotech Gets FDA Expanded Access - Orange County Business Journal
NKGen Secures FDA Expanded Access For NK Cell Therapy In Neurodegenerative Diseases, Stock Down - Nasdaq
FDA grants expanded access for NKGen’s cell therapy in neurodegenerative diseases By Investing.com - Investing.com South Africa
FDA grants expanded access for NKGen’s cell therapy in neurodegenerative diseases - Investing.com Nigeria
NKGen Receives FDA Expanded Access Protocol Authorization for Landmark Treatment of Several Neurodegenerative Diseases - The Manila Times
NKGen Receives FDA Expanded Access Protocol Authorization - GlobeNewswire
FDA Grants Breakthrough Access: NKGen's NK Cell Therapy Now Available for Multiple Untreatable Brain Diseases - Stock Titan
NKGen Biotech and HekaBio enter strategic partnership to bring novel NK cell therapy to Japan - BioSpectrum Asia
NKGen Biotech and HekaBio Enter Strategic Partnership to Bring Novel NK Cell Therapy to Japan - The Manila Times
NKGen Biotech Partners with HekaBio for SNK01 in Japan - TipRanks
NKGen and HekaBio partner to advance NK cell therapy in Japan - Investing.com India
NKGen and HekaBio partner to advance NK cell therapy in Japan By Investing.com - Investing.com South Africa
Vivos Therapeutics shares rise 1.81% premarket after NKGen Biotech's new funding announcement. - AInvest
Revolutionary NK Cell Therapy Targets Alzheimer's: NKGen Secures Fast-Track Access to Japanese Market - Stock Titan
NKGen Biotech Announces New Funding to Regain Compliance with Reporting Obligations and Listing Standards - GlobeNewswire
NKGen Biotech (NYSE:NKGN) versus CEL-SCI (NYSE:CVM) Head-To-Head Comparison - Defense World
4.30%
0.32%
Kapitalisierung:
|
Volumen (24h):